Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000329116 | SCV000337970 | uncertain significance | not provided | 2015-12-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001088526 | SCV000640958 | likely benign | Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 10 | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000329116 | SCV003832195 | benign | not provided | 2023-04-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003362744 | SCV004056130 | uncertain significance | Inborn genetic diseases | 2023-07-05 | criteria provided, single submitter | clinical testing | The c.161G>A (p.R54H) alteration is located in exon 3 (coding exon 3) of the DOK7 gene. This alteration results from a G to A substitution at nucleotide position 161, causing the arginine (R) at amino acid position 54 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV000329116 | SCV005327512 | uncertain significance | not provided | 2024-03-13 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 26198629, 20012313, 20603078) |